Filing Flows › Sutro Biopharma (STRO) › Q2 2026 › vs Q2 2025
Sutro Biopharma (STRO) Q2 2026 vs Q2 2025 (year over year)
Sutro Biopharma's revenue fell $53.9M (-85%) from $63.7M in Q2 2025 to $9.8M in Q2 2026.
Sutro Biopharma, Q2 2026: revenue $9.8M (-85% year over year), operating margin -303.8%, net loss $38.5M, operating cash flow −$38.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.8M | $63.7M | −$53.9M | -85% |
| Net loss | $38.5M | $11.5M | $27.0M | +235% |
| Costs & expenses | $48.4M | $75.3M | −$26.9M | -36% |
| Operating costs | $39.7M | $67.1M | −$27.4M | -41% |
| Interest & other, net | $8.6M | $8.2M | $472K | +6% |
| Income tax | $1K | −$18K | $19K | — |
| Research & development | $31.7M | $38.3M | −$6.6M | -17% |
| General & admin | $7.8M | $10.3M | −$2.5M | -24% |
| Other operating costs | $201K | $18.4M | −$18.2M | -99% |
| Operating cash sources | $41.6M | $51.9M | −$10.3M | -20% |
| Depreciation & amortization | $1.3M | $1.9M | −$638K | -34% |
| Share-based compensation | $2.0M | $5.3M | −$3.3M | -62% |
| Cash used in operations | $38.3M | $44.7M | −$6.4M | -14% |
| Net loss absorbed | $38.5M | $11.5M | $27.0M | +235% |
| Working capital & other | $3.0M | $40.4M | −$37.4M | -93% |
Questions
How much did Sutro Biopharma's revenue grow year over year in Q2 2026?
Sutro Biopharma's revenue fell $53.9M (-85%) from $63.7M in Q2 2025 to $9.8M in Q2 2026.